Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Company announcement No. 23 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 23, 2026) Copenhagen, Denmark, June 8, 2026 – Zealand Pharma A/S ("the Company" or “Zealand...
-
Company announcement – No. 22 / 2026 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, June 8, 2026 – Zealand Pharma A/S (“Zealand...
-
Company announcement No. 21 / 2026 Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass...
-
Press release – No. 13 / 2026 New data from Phase 2 ZUPREME-1 trial at the American Diabetes Association 2026 Scientific Sessions further support potential of petrelintide to redefine the weight...
-
Press release – No. 12 / 2026 Zealand Pharma to participate in the Goldman Sachs Global Healthcare Conference Copenhagen, Denmark, June 2, 2026 - Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no....
-
Company announcement No. 20 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 22, 2026) Copenhagen, Denmark, June 1, 2026 – Zealand Pharma A/S ("the Company" or “Zealand...
-
Company announcement – No. 19 / 2026 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons ...
-
Press release – No. 11 / 2026 Zealand Pharma to participate in the Jefferies Global Healthcare Conference Copenhagen, Denmark, May 27, 2026 - Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a...
-
Press release – No. 10 / 2026 Zealand Pharma to Present Data atthe American Diabetes Association's 2026 Scientific Sessions Late-breaking Phase 2 ZUPREME-1 data on petrelintide to be featured as...
-
Company announcement No. 18 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 21, 2026) Copenhagen, Denmark, May 26, 2026 – Zealand Pharma A/S ("the Company" or “Zealand...